Dr. Yi Zhao 赵毅
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of blood disorders including anemia, leukopenia, immune thrombocytopenia, acute leukemia, multiple myeloma, malignant lymphoma, and myelodysplastic syndromes.
Dr. Zhao holds a medical doctorate and serves as a master’s supervisor. Since obtaining a master’s degree in hematology in 2001, Dr. Zhao has worked in clinical hematology. A PhD was earned from Zhejiang University School of Medicine in 2011. Training included periods at the Royal Free Hospital in the UK and the International Myeloma Foundation in the US. Dr. Zhao previously served as Administrative Director of Hematology at Yiwu Central Hospital and currently leads a medical group at the First Affiliated Hospital.
Professional roles
- Member, Lymphoma Branch, China Medical Education Association
- Member, Hematology Branch, Zhejiang Immunological Society
- Member, Hematology Professional Committee, Zhejiang Cancer Alliance
- Vice Chair, Blood and Lymphatic Tumor Professional Committee, Jinhua Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Yi). Papers usually list the name as Yi Zhao or Zhao Y.
Selected publications
45 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Case Rep, 2026 (senior author): Therapy-Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review. PubMed 41635424
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2025 (senior author): [Efficacy and Safety of Polatuzumab Vedotin Combined with Chemotherapy in the Treatment of Relapsed and Refractory Diffuse Large B-Cell Lymphoma]. PubMed 41502256
- Ann Hematol, 2025 (senior author): Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study. PubMed 40694078
- Hematology, 2024 (senior author): Pre-treatment [(18)F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma. PubMed 38465661
- J Cancer Res Clin Oncol, 2024 (senior author): Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma. PubMed 38587664
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2023 (senior author): [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients]. PubMed 37551477
- BMC Infect Dis, 2023 (senior author): Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia patient. PubMed 37029352
- Comput Math Methods Med, 2022 (senior author): Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China. PubMed 35096126
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion